Clinical study of Pabolizumab for neoadjuvant therapy of Siewert II/III adenocarcinoma of the esophagogastric junction

Efficacy and safety of pabolizumab versus SOX regimen for neoadjuvant therapy in Siewert II/III adenocarcinoma of the esophagogastric junction: a multicenter, open, randomized controlled clinical trail

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046070

Enrollment

Unknown

Registered

2021-05-03

Start date

2021-06-01

Completion date

Unknown

Last updated

2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of the esophagogastric junction

Interventions

control group:SOX regimen

experimental group:Pabolizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adenocarcinoma of the esophagogastric junction diagnosed by histopathology; 2. Siewert types II and III; 3. The clinical stage of T3+N0M0 or TxN+M0; 4. Agree to conduct MMR / MSI test and the result is dMMR / MSI-H; 5. Can tolerant immunotherapy and chemotherapy; 6. The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up.

Exclusion criteria

Exclusion criteria: 1. Participating in other clinical investigates; 2. Other chemotherapy history.

Design outcomes

Primary

Measure	Time frame
Tumor regression grading;	—

Secondary

Measure	Time frame
R0 resection rate;Serious adverse events;Immune related adverse events;Overall response rate;Overall survival;	—

Countries

China

Contacts

Public ContactZhang Chaojun

The First Medical Center of the PLA General Hospital

zcjdlyxzx@163.com+86 18600317036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026